P3, N=50, Active, not recruiting, Mansoura University

P3, N=375, Completed, Tonix Pharmaceuticals, Inc. | Terminated --> Completed

P3, N=148, Completed, Sir Mortimer B. Davis - Jewish General Hospital | Recruiting --> Completed

P2, N=180, Not yet recruiting, University of North Carolina, Chapel Hill | Initiation date: Oct 2024 --> Jan 2025

P3, N=180, Completed, Beni-Suef University

P=N/A, N=6, Completed, McMaster University | Unknown status --> Completed | N=20 --> 6

P2, N=60, Recruiting, Lawson Health Research Institute | Trial completion date: May 2025 --> Feb 2026 | Initiation date: Jul 2024 --> Oct 2024 | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2024 --> Dec 2025

P4, N=170, Active, not recruiting, Kantonsspital Graubünden | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024

P2, N=180, Not yet recruiting, University of North Carolina, Chapel Hill

P2, N=36, Not yet recruiting, University of Wisconsin, Madison

P2, N=36, Not yet recruiting, University of Wisconsin, Madison

P3, N=200, Not yet recruiting, Shanghai Fourth People's Hospital Affiliated to Tongji University; Shanghai Fourth People's Hospital

P2, N=36, Not yet recruiting, Austin Hospital

P2, N=18, Recruiting, Austin Health | Not yet recruiting --> Recruiting

P1, N=30, Active, not recruiting, GenesisCare | Recruiting --> Active, not recruiting

P3, N=70, Recruiting, VA Office of Research and Development | Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Jun 2024 --> Jan 2025

P=N/A, N=229, Completed, NPO Petrovax

P1, N=28, Completed, Dexa Medica Group

P1, N=50, Not yet recruiting, Lawson Health Research Institute

P3, N=545, Recruiting, Ocuphire Pharma, Inc.

P1, N=100, Active, not recruiting, The Cleveland Clinic | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Oct 2024

Eighty-six female rats were exposed for 72 h to normoxia or normobaric hypoxia and received infusions with NaCl, prazosin, propranolol, or prazosin-propranolol combination. The results suggest that hypoxia-induced sympathetic activation contributes to inflammation and nitrosative stress in the lungs but not to PE. We suggest that AB in hypoxia aggravates hypoxia-induced inotropic LV dysfunction and backlog into the pulmonary circulation, thus promoting PE.

P1, N=28, Completed, Zenith Technology Corp Ltd | Recruiting --> Completed

P4, N=89, Completed, Seattle Institute for Biomedical and Clinical Research | N=228 --> 89

P3, N=150, Recruiting, Tanta University

P1/2, N=89, Completed, VA Office of Research and Development | N=166 --> 89

P3, N=183, Completed, NorthShore University HealthSystem | Recruiting --> Completed

P2, N=60, Not yet recruiting, Lawson Health Research Institute | Initiation date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2025 --> Dec 2024

P3, N=90, Terminated, Mayo Clinic | N=350 --> 90 | Recruiting --> Terminated; Slow recruitment and enrollment

Our data indicated that the combination of metformin with AA and the combination of metformin, silodosin and AA decreased the hTERT levels when compared to control, AA, and silodosin with AA. The administration of metformin resulted in a reduction of hTERT levels in the PC3 cell line, but the impact of silodosin on hTERT levels was not statistically significant compared to AA group.

P4, N=30, Not yet recruiting, University of Southern California | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jul 2024 --> Jul 2026

P1/2, N=127, Recruiting, Hackensack Meridian Health | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026

P3, N=200, Recruiting, Ocuphire Pharma, Inc.

P3, N=146, Not yet recruiting, Foundation for Advancing Veterans' Health Research

P4, N=228, Completed, Seattle Institute for Biomedical and Clinical Research | Trial completion date: Dec 2024 --> Jun 2023 | Trial primary completion date: Dec 2023 --> May 2023 | Active, not recruiting --> Completed

Based on our findings, a mechanism of cell death was not able to be established due to lack of cleaved caspase-3 expression. Capable of bypassing many aspects of the lengthy, costly, and difficult cancer drug approval process, chlorpromazine and prazosin deserve further investigation for use in conjunction with traditional chemotherapeutics.

Our findings demonstrated abnormalities in S100B and WM microstructure in patients with schizophrenia. These abnormalities may be partly reversed by quetiapine treatment.

P3, N=212, Recruiting, Emory University | Not yet recruiting --> Recruiting

Because of its non-elevated serum PSA level, prostate SRCT is often ignored as a possibility of malignant tumor and regarded as benign prostatic hyperplasia (BPH). The possibility of prostate SRCT need to be considered if dysuria symptoms could not alleviate significantly after a period of oral treatment.

The expression alterations of breast cancer resistance protein (BCRP) and organic anion transporting polypeptide (OATP) 2B1 were determined at the mRNA and protein levels, and the subsequent functional alterations were evaluated via an accumulation study with the representative transporter substrates [prazosin and dibromofluorescein (DBF)] and SN-38...Treatment with rifampin or novobiocin supported the significant roles of BCRP and OATP2B1 in the transport and cytotoxic profile of SN-38. Collectively, these results suggest that BCRP and OATP2B1 are involved in the increased cytotoxicity of SN-38 under inflammatory conditions in vitro. Further comprehensive research is warranted to completely understand SN-38-induced gastrointestinal cytotoxicity and aid in the successful treatment of cancer with irinotecan.

P3, N=212, Not yet recruiting, Emory University

P2, N=64, Not yet recruiting, Lawson Health Research Institute